FDA’s 503B GLP-1 bulks-list proposal: what happens after the July 2026 comment period

01

What changed on July 30—and what did not

FDA published a May 1, 2026 notice proposing not to place semaglutide, tirzepatide, or liraglutide on the list of bulk drug substances for which there is a clinical need for outsourcing facilities to use in compounding. The agency later extended the comment period by 30 days. The electronic docket accepted timely comments through 11:59 p.m. Eastern Time on July 30.

Closing a comment period ends a public-input window; it does not make the proposal final. FDA said comments would inform its final determination. Until the agency publishes that determination, accurate reporting should use proposed, tentative, or pending—not banned, removed, finalized, or newly illegal.

The terminology matters because none of the three substances was being removed from an existing 503B Bulks List entry. FDA’s April announcement said the agency was proposing to exclude them after evaluating nominations. A provider statement that FDA removed an already-listed GLP-1 would misdescribe the record.

02

What the 503B Bulks List controls

Section 503B creates conditions under which an FDA-registered outsourcing facility can qualify for exemptions from several ordinary drug-law requirements. One condition concerns the source of the active ingredient. In most circumstances, an outsourcing facility may compound from a bulk drug substance only when that substance appears on the 503B Bulks List or the finished drug appears on FDA’s drug-shortage list at the relevant times.

The list is not an approved-drug catalog. Inclusion would not mean FDA had reviewed a compounded finished product for safety, effectiveness, or quality. Exclusion would not withdraw an approved brand or generic product. The inquiry is whether there is a clinical need for outsourcing facilities to compound from that bulk substance under this particular statutory pathway.

Registration also has a narrow meaning. A 503B outsourcing facility is registered with FDA and subject to specific federal requirements, but FDA does not preapprove every compounded batch. Consumers still need the exact facility, product, lot, label, dispensing pathway, and current inspection or recall context.

03

Why FDA proposed not to include the three substances

FDA’s notice evaluates semaglutide, tirzepatide, and liraglutide separately, then reaches the same tentative conclusion: the record did not establish a clinical need for outsourcing facilities to compound from bulk. The agency considered available approved products, nominated uses, proposed formulation changes, medical need, and safety issues.

The notice discusses approved presentations and whether proposed differences would address an attribute that makes an approved product medically unsuitable for certain patients. It does not say that cost, convenience, or a clinic’s preferred subscription model alone establishes the statutory clinical-need standard.

That is a policy analysis, not individualized medical advice. It also is not a finding that every patient has identical needs. FDA’s task in this proceeding is to apply the section 503B clinical-need standard to nominated bulk substances, while a licensed clinician evaluates an individual and applicable law governs any prescription.

04

Keep shortage compounding and 503A separate

FDA’s notice explains that an outsourcing facility may have a separate route to use a bulk drug substance when the drug compounded from it appears on FDA’s shortage list at the time of compounding, distribution, and dispensing. That exception depends on the official shortage record and transaction dates. A local back order or a provider’s statement that supply is tight is not the same as an FDA-listed nationwide shortage.

Section 503A is a different framework centered on patient-specific prescription compounding by qualifying state-licensed pharmacies or physicians. It has its own bulk-substance and essentially-a-copy conditions. A decision about the 503B Bulks List should not be restated as if it automatically resolved every 503A question.

Neither pathway turns a compounded drug into an FDA-approved drug or generic. FDA states that compounded drugs do not receive its premarket review for safety, effectiveness, and quality. Provider copy should name the pathway without using registered, shortage, or custom as a substitute for approved.

05

How to evaluate claims while the final decision is pending

Start with the dated FDA policy page and the Federal Register docket. Look for a later final notice, withdrawal, reopened comment period, or court order. Do not rely on an undated clinic FAQ or a screenshot of the May proposal after the agency record changes.

For a specific product, record the date it was compounded, distributed, and dispensed; the name and registration type of the pharmacy; the active ingredient and source; and the reason the provider says compounding qualifies. Then compare the relevant dates with FDA’s shortage status and the final bulks-list record.

If a provider says a customized formulation falls outside an essentially-a-copy restriction, ask for the prescriber’s documented patient-specific clinical difference. The answer may be important under a compounding policy, but it does not prove FDA approval, equivalence to an approved product, or suitability for the patient.

• →Final Federal Register status
• →FDA shortage status on each relevant date
• →503A or 503B pathway
• →Exact pharmacy and product
• →Patient-specific prescription where required
• →No claim of FDA approval for the compounded product

06

What consumers should do now

Consumers do not need to make a treatment change solely because a comment period ended. A person using a prescription product should take product and access questions to the licensed prescriber and dispensing pharmacist, who can identify the exact drug and current lawful pathway. Abrupt treatment decisions based on a headline can create a different safety problem.

When comparing providers, favor those that date regulatory claims, identify the dispensing pharmacy before payment, state whether the product is FDA-approved or compounded, and avoid predicting FDA’s final action. A sales page that presents a pending proposal as settled law is a warning sign about research quality.

This article will require an update when FDA issues a final determination. The durable lesson is procedural: identify the legal question, use the primary record, match dates, and keep approval, shortage, registration, and compounding status in separate fields.